Q4 2025 Thermo Fisher Scientific Inc Earnings Call Transcript
Key Points
- Thermo Fisher Scientific Inc (TMO) delivered strong financial performance in 2025, with a 7% year-over-year revenue growth in Q4 and a 4% increase for the full year.
- The company achieved high single-digit growth in its bioproduction business and mid-single-digit growth in clinical research, showcasing strong performance in key segments.
- Thermo Fisher Scientific Inc (TMO) launched several high-impact products, including the Thermo Scientific Orbitrap Astral Zoom and the Thermo Scientific Krios 5 Cryo-TEM, enhancing its leadership in innovation.
- The company successfully executed its capital deployment strategy, committing $13 billion to M&A and returning $3.6 billion to shareholders through stock buybacks and dividends.
- Thermo Fisher Scientific Inc (TMO) expanded its global footprint, including the opening of a new bioprocess design center in India, strengthening its support for customers worldwide.
- The academic and government market faced challenges, with low single-digit declines in both Q4 and the full year, impacted by macro conditions in the US and China.
- The Analytical Instruments segment experienced flat organic revenue growth in Q4 and the full year, with pressures from tariffs and related FX affecting margins.
- Despite strong operational performance, the adjusted operating margin in Q4 was 23.6%, 30 basis points lower than the previous year, due to over 100 basis points of headwind from tariffs and FX.
- The company's free cash flow was slightly lower than expected, driven by temporary impacts in working capital and the timing of cash taxes.
- Thermo Fisher Scientific Inc (TMO) anticipates a cautious environment in the US academic and government sectors for 2026, with spending expected to remain cautious until a finalized NIH budget is passed.
Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2025 fourth-quarter conference call. (Operator Instructions)
I would now like to introduce our moderator for the call, Mr. Rafael Tejada, Vice President, Investor Relations. Mr. Tejada, you may begin the call.
Good morning and thank you for joining us. On the call with me today is Marc Casper, our Chairman, President, and Chief Executive Officer; and Stephen Williamson, Senior Vice President and Chief Financial Officer.
Please note this call is being webcast live and will be archived on the Investors section of our website, thermofisher.com, under the heading, News, Events and Presentations until April 22, 2026. A copy of the press release of our fourth-quarter and full-year 2025 earnings is available in the Investors section of our website under the heading Financials.
So before we begin, let me briefly cover our Safe Harbor statement. Various remarks that we may make
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
